Petrylak DP - Search Results

1

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK. Fizazi K, et al. Among authors: petrylak dp. Eur J Cancer. 2022 Jan;160:61-71. doi: 10.1016/j.ejca.2021.09.043. Epub 2021 Nov 18. Eur J Cancer. 2022. PMID: 34802864 Free article. Clinical Trial.

2

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Petrylak DP, et al. Cancer. 1992 Dec 15;70(12):2870-8. doi: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. Cancer. 1992. PMID: 1451069

3

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.

Yagoda A, Petrylak D. Yagoda A, et al. Cancer. 1993 Feb 1;71(3 Suppl):1098-109. doi: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g. Cancer. 1993. PMID: 7679039 Review.

4

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C. Petrylak DP, et al. Semin Oncol. 1999 Oct;26(5 Suppl 17):28-33. Semin Oncol. 1999. PMID: 10604266 Clinical Trial.

5

A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.

Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP. Tiersten AD, et al. Among authors: petrylak dp. Cancer. 2003 Feb 1;97(3):537-44. doi: 10.1002/cncr.11082. Cancer. 2003. PMID: 12548594 Free article. Clinical Trial.

6

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Petrylak DP, et al. N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Free article. Clinical Trial.

7

Chemotherapy for androgen-independent prostate cancer.

Petrylak DP. Petrylak DP. World J Urol. 2005 Feb;23(1):10-3. doi: 10.1007/s00345-004-0482-0. Epub 2005 Feb 1. World J Urol. 2005. PMID: 15685445 Review.

8

Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?

Bhandari MS, Petrylak DP, Hussain M. Bhandari MS, et al. Among authors: petrylak dp. Eur J Cancer. 2005 Apr;41(6):941-53. doi: 10.1016/j.ejca.2005.02.008. Eur J Cancer. 2005. PMID: 15808960 Review.

9

Chemotherapy agents and timing of chemotherapy in prostate cancer management.

Donohue KM, Petrylak DP. Donohue KM, et al. Among authors: petrylak dp. Curr Urol Rep. 2005 May;6(3):224-7. doi: 10.1007/s11934-005-0011-8. Curr Urol Rep. 2005. PMID: 15869727 Review.

10

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED. Vaishampayan UN, et al. Among authors: petrylak dp. Cancer. 2005 Oct 15;104(8):1627-32. doi: 10.1002/cncr.21370. Cancer. 2005. PMID: 16138364 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page